Accretion Pharmaceuticals
- Market cap
- ₹ 202 Cr.
- P/E
- 21.3x
- P/B
- 3.85x
- 52-week range
- 54.6 – 220
- ROE
- 28%
- ROCE
- 28.9%
- Dividend yield
- 0%
- Debt / equity
- 0.23
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE SME
About
Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Accretion Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)21.3 against a typical 34.3: cheaper than most peers (1st = cheapest).71st of 220
- Sales growth+243.7% against a typical +15.6% from a year earlier.9th of 197
- Profit growth+230.2% against a typical +18.9% from a year earlier.17th of 160
- Share price, 3 months+12.1% against a typical −0.5%.57th of 200
- Size₹ 202.4 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).117th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 31 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 8 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 10 Jun 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2025 and other business matters |
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 13 | 19 | 39 | 44 | 46 |
| Expenses | 11 | 14 | 31 | 37 | 38 |
| Operating Profit | 3 | 4 | 8 | 7 | 8 |
| OPM % | 19.3% | 23.3% | 19.4% | 16.2% | 17.2% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 1 | 1 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 2 | 3 | 6 | 6 | 7 |
| Tax % | 25% | 25.2% | 33.1% | 25.9% | 26.2% |
| Net Profit | 1 | 2 | 4 | 5 | 5 |
| EPS in Rs | 3.72 | 3.01 | 5.3 | 4.27 | 4.43 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 56%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- 42%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 35%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Accretion Pharmaceuticals | ₹ 185.00 | ₹ 202 Cr. | 21.3x | 3.9x | 28% | — |
| Sun Pharmaceutical Industries | ₹ 1,748.00 | ₹ 4,19,394 Cr. | 38.5x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,950.00 | ₹ 2,37,594 Cr. | 73x | 11.4x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,338.00 | ₹ 1,08,059 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,129.40 | ₹ 1,12,658 Cr. | 21.2x | 4.3x | 19.7% | 18.5% |
Management
- Harshad Nanubhai Rathod
- Executive Chairman of the Board, Chief Financial Officer
- Bhavika Dhaval Makadia
- Company Secretary, Compliance Officer
- Vivek Ashok Kumar Patel
- Managing Director, Executive Director
- Hardik Mukundbhai Prajapati
- Executive Director
- Mayur Popatlal Sojitra
- Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.